Statins: can the new generation make an impression?
Statins: can the new generation make an impression?
复制标题
他汀类药物：新一代能否给人留下深刻印象？
DOI：
--
复制
发表时间：
2004
影响因子：
3.4
通讯作者：
R. Rosenson
中科院分区：
文献类型：
--
作者：
R. Rosenson
尽管大规模的他汀类药物试验显示显著降低了心血管风险，但仍有许多患者在接受他汀类药物治疗的情况下仍有心血管事件。越来越多的证据表明，低密度脂蛋白胆固醇(LDL-C)的较大降低与心血管发病率和死亡率的较大改善有关，这突显了对更有效的他汀类药物的需求。本文就两种新的他汀类药物瑞舒伐他汀和匹伐他汀的调脂作用作一综述。瑞舒伐他汀代表了其他现有药物的药理和临床特性的进步。使用瑞舒伐他汀可以显著降低低密度脂蛋白胆固醇，即使在起始剂量为10毫克的情况下，在从其他他汀类药物转向10毫克的患者中也是如此，这应该有助于提高目标实现程度，同时减少剂量滴定的需要。瑞舒伐他汀改善血脂谱其他成分的能力，如高密度脂蛋白胆固醇(高密度脂蛋白胆固醇)、甘油三酯和非高密度脂蛋白胆固醇，可能对糖尿病和代谢综合征患者有用。高密度脂蛋白胆固醇的升高，加上瑞舒伐他汀在降低低密度脂蛋白胆固醇和非高密度脂蛋白胆固醇方面的更大疗效，可能会消除联合治疗的需要。瑞舒伐他汀的一些结果研究结果预计将在未来5年内公布，这将有助于他汀类药物治疗和心血管疾病预防的证据基础。
Although large-scale statin trials have demonstrated significant reductions in cardiovascular risk, there are many patients who have a cardiovascular event despite receiving statin therapy. There is increasing evidence that larger reductions in low-density lipoprotein cholesterol (LDL-C) are associated with greater improvements in cardiovascular morbidity and mortality, which highlights the need for more efficacious statins. This article will review the lipid-altering effects of two new statins, rosuvastatin and pitavastatin. Rosuvastatin represents an advance in the pharmacological and clinical properties of other available agents. The large LDL-C reductions observed with rosuvastatin, even at the start dose of 10 mg and in patients switched from other statins to rosuvastatin 10 mg, should help to improve goal attainment, while reducing the need for dose titration. The ability of rosuvastatin to improve other elements of the lipid profile, such as high-density lipoprotein cholesterol (HDL-C), triglycerides and non-HDL-C, may be of utility in patients with diabetes and the metabolic syndrome. Increases in HDL-C, along with the greater efficacy of rosuvastatin for reducing LDL-C and non-HDL-C, may obviate the need for combination therapy. Results of a number of outcome studies with rosuvastatin are expected over the next 5 years, which will contribute to the evidence base for statin therapy and cardiovascular disease prevention.
富含甘油三酯的脂蛋白和动脉粥样硬化的进展。
影响因子：
39.3
作者：
Hodis,HN;Mack,WJ
通讯作者：
Mack,WJ
DOI：
10.1016/s1062-1458(01)00460-3
发表时间：
2001-06
期刊：
The New England journal of medicine
影响因子：
--
作者：
P. Ridker;N. Rifai;M. Clearfield;J. R. Downs;S. E. Weis;J. S. Miles;A. M. Gotto
通讯作者：
P. Ridker;N. Rifai;M. Clearfield;J. R. Downs;S. E. Weis;J. S. Miles;A. M. Gotto